Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response

Modern Pathology

Volumn 28, Issue 10, 2015, Pages 1315-1323

  Pizzi, Marco ^a,b   Silver, Richard T ^a   Barel, Ariella ^a   Orazi, Attilio ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA INTERFERON; ALPHA INTERFERON; JAK2 PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BONE MARROW BIOPSY; BONE MARROW CELL; CELL DENSITY; CELL STRUCTURE; CELLULAR PARAMETERS; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG RESPONSE; FEMALE; GENE MUTATION; HISTOLOGY; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MALE; MEGAKARYOCYTE; MEGAKARYOCYTE DENSITY; MEGAKARYOCYTE TIGHT CLUSTER; MEGAKARYOCYTIC ATYPIA; MIDDLE AGED; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOID TO ERYTHROID RATIO; NAKED NUCLEI DENSITY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPLENOMEGALY; THROMBOCYTHEMIA; FLOW CYTOMETRY; GENETICS; IMMUNOHISTOCHEMISTRY; MUTATION; PATHOLOGY; PRIMARY MYELOFIBROSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-ALPHA; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; PRIMARY MYELOFIBROSIS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84942983937     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2015.93     Document Type: Article

References (34)

1. Vardiman JW, Porwit A, Brunning RD et al. Introduction and overview of the classification of the myeloid neoplasms. In: Swerdlow SH, Campo E, Harris NL et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th (edn). International Agency for Research on Cancer: Lyon, France, 2008, pp 18-30.
2. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22.
3. Pozdnyakova O, Hasserjian RP, Verstovsek S et al. Impact of bone marrow pathology on the clinical management of Philadelphia chromosome-negative myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk 2015;15:253-261.
4. Mascarenhas JO, Orazi A, Bhalla KN et al. Advances in myelofibrosis: a clinical case approach. Haematologica 2013;98:1499-1509.
5. Levine RL, Pardanani A, Tefferi A et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007;7:673-683.
6. Nangalia J, Massie CE, Baxter EJ et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369: 2391-2405.
7. Cervantes F, Dupriez B, Pereira A et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelo-fibrosis Research and Treatment. Blood 2009;113: 2895-2901.
8. Cervantes F, Dupriez B, Passamonti F et al. Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol 2012;30:2981-2987.
9. Cervantes F. How I treat myelofibrosis. Blood 2014;124: 2635-2642.
10. Passamonti F, Maffioli M, Cervantes F et al. Impact of ruxolitinib on the natural history of primary myelofi-brosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood 2014;123:1833-1835.
11. Wang X, Ye F, Tripodi J et al. JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis. Blood 2014;124:2987-2995.
12. Cervantes F, Vannucchi AM, Kiladjian JJ et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013;122:4047-4053.
13. Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombo-cythemia and myelofibrosis. Expert Rev Hematol 2013;6:49-58.
14. Quintas-Cardama A, Abdel-Wahab O, Manshouri T et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a. Blood 2013;122:893-901.
15. Silver RT, Vandris K, Goldman JJ. Recombinant interferon-alpha may retard progression of early primary myelofibrosis: a preliminary report. Blood 2011;117: 6669-6672.
16. Silver RT, Vandris K. Recombinant interferon alpha (rIFN alpha-2b) may retard progression of early primary myelofibrosis. Leukemia 2009;23:1366-1369.
17. Ianotto JC, Boyer-Perrard F, Gyan E et al. Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups. Br J Haematol 2013;162:783-791.
18. Stauffer Larsen T, Iversen KF et al. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leuk Res 2013;37:1041-1045.
19. Nguyen HM, Kiladjian JJ. Is there a role for the use of IFN-α in primary myelofibrosis? Hematol Am Soc Hematol Educ Program 2012;2012:567-570.
20. Tefferi A, Cervantes F, Mesa R et al. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 2013;122: 1395-1398.
21. Geyer HL, Mesa RA. Therapy for myeloproliferative neoplasms: when, which agent, and how? Blood 2014;124:3529-3537.
22. Chott A, Gisslinger H, Thiele J et al. Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis. Br J Haematol 1990;74:10-16.
23. Radin AI, Kim HT, Grant BW et al. Phase II study of alpha2 interferon in the treatment of the chronic myelo-proliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group. Cancer 2003;98: 100-109.
24. Cervantes F, Alcorta I, Escoda L et al. Alpha interferon treatment of idiopathic myelofibrosis. Med Clin (Barc) 1993;101:498-500.
25. Schmitt A, Jouault H, Guichard J et al. Pathologic interaction between megakaryocytes and polymorpho-nuclear leukocytes in myelofibrosis. Blood 2000;96: 1342-1347.
26. Centurione L, Di Baldassarre A, Zingariello M et al. Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1(low) mice. Blood 2004;104:3573-3580.
27. Wen Q, Goldenson B, Crispino JD. Normal and malignant megakaryopoiesis. Expert Rev Mol Med 2011;13:e32.
28. Gewirtz AM. Human megakaryocytopoiesis. Semin Hematol 1986;23:27-42.
29. Mullally A, Bruedigam C, Poveromo L et al. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-alpha in a murine model of polycythemia vera. Blood 2013;121:3692-3702.
30. Stein BL, Tiu RV. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms. J Interferon Cytokine Res 2013;33:145-153.
31. Vazquez MI, Catalan-Dibene J, Zlotnik A. B cells responses and cytokine production are regulated by their immune microenvironment. Cytokine 2015;74: 318-326.
32. Tefferi A, Vaidya R, Caramazza D et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independ-ently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011;29:1356-1363.
33. Kleppe M, Kwak M, Koppikar P et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov 2015;5:316-331.
34. Tefferi A, Lasho TL, Finke CM et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 2014;28:1472-1477.